Ashish Goel

Ashish Goel

Auto-generated profile, based on publicly available information

Ashish Goel

Department of Hepatology, Christian Medical College, Vellore 632 004, India

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
MMMarta Magaz
Marta Magaz
HGHeloïse Giudicelli-Lett
Heloïse Giudicelli-Lett
JAJuan G. Abraldes
Juan G. Abraldes
OFOANA FARCAU-NICOARA
OANA FARCAU-NICOARA
FTFanny Turon
Fanny Turon
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán

18 July 2021 in Hepatology International
Verified
Journal Article
Closed access
PDF file
NVNipun Verma
Nipun Verma
RDRadha Krishan Dhiman
Radha Krishan Dhiman
ACAshok Choudhury
Ashok Choudhury
STSunil Taneja
Sunil Taneja
ADAjay Duseja
Ajay Duseja
APAPASL ACLF Research Consortium (AARC) for APASL ACLF working Party
APASL ACLF Research Consortium (AARC) for APASL ACLF working Party

15 November 2024 in Hepatology International
Verified
Journal Article
Open access
PDF file
ASAkash Shukla
Akash Shukla
DRDon C. Rockey
Don C. Rockey
PKPatrick S. Kamath
Patrick S. Kamath
DKDavid E. Kleiner
David E. Kleiner
ASAnkita Singh
Ankita Singh
SSShiv Kumar Sarin
Shiv Kumar Sarin
Since the Asian Pacific Association for the Study of the Liver (APASL) published guidelines on non-cirrhotic portal fibrosis/idiopathic portal hypertension in 2007, there has been a surge in new information, especially with the introduction of the term porto-sinusoidal vascular disorder (PSVD). Non-cirrhotic intra-hepatic causes of portal hypertension include disorders with a clearly identifiable etiology, such as schistosomiasis, as well as disorders with an unclear etiology such as non-cirrhotic portal fibrosis (NCPF), also termed idiopathic portal hypertension (IPH). This entity is being increasingly recognized as being associated with systemic disease and drug therapy, especially cancer therapy. An international working group with extensive expertise in portal hypertension was assigned with formulating consensus guidelines to clarify the definition, diagnosis, histological features, natural history, and management of NCPF/IPH, especially in the context of PSVD. The guidelines were prepared based on evidence from existing published literature. Whenever there was paucity of evidence, expert opinion was included after detailed deliberation. The goal of this manuscript, therefore, is to enhance the current understanding and help create global consensus on the issues surrounding NCPF/IPH.

12 November 2022 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
LTLeenath Thomas
Leenath Thomas
JCJolly Chandran
Jolly Chandran
AGAshish Goel
Ashish Goel
EJEbor Jacob
Ebor Jacob
BCBinila Chacko
Binila Chacko
UZUday Zachariah
Uday Zachariah

22 April 2024 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
PAPorkizhi Arjunan
Porkizhi Arjunan
DKDurga Kathirvelu
Durga Kathirvelu
GMGokulnath Mahalingam
Gokulnath Mahalingam
AGAshish Kumar Goel
Ashish Kumar Goel
UZUday George Zacharaiah
Uday George Zacharaiah
SMSrujan Marepally
Srujan Marepally
Inherited genetic disorders of the liver pose a significant public health burden. Liver transplantation is often limited by the availability of donor livers and the exorbitant costs of immunosuppressive therapy. To overcome these limitations, nucleic acid therapy provides a hopeful alternative that enables gene repair, gene supplementation, and gene silencing with suitable vectors. Though viral vectors are the most efficient and preferred for gene therapy, pre-existing immunity debilitating immune responses limit their use. As a potential alternative, lipid nanoparticle-mediated vectors are being explored to deliver multiple nucleic acid forms, including pDNA, mRNA, siRNA, and proteins. Herein, we discuss the broader applications of lipid nanoparticles, from protein replacement therapy to restoring the disease mechanism through nucleic acid delivery and gene editing, as well as multiple preclinical and clinical studies as a potential alternative to liver transplantation.

15 June 2023 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
AGAshish Goel
Ashish Goel
UZUday Zachariah
Uday Zachariah
DDDolly Daniel
Dolly Daniel
CEChundamannil E. Eapen
Chundamannil E. Eapen